Hudson Bay Capital Management
ALNY icon

Hudson Bay Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hudson Bay Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.8M Buy
148,720
+108,720
+272% +$32.8M 0.12% 128
2026
Q1 		$13.2M Sell
40,000
-45,000
-53% -$15.3M 0.05% 262
2025
Q4 		$33.8M Buy
85,000
+75,589
+803% +$33.5M 0.11% 167
2025
Q3 		$4.29M Sell
9,411
-5,937
-39% -$2.42M 0.01% 593
2025
Q2 		$5M Buy
+15,348
New +$4.25M 0.02% 547
2025
Q1 		– Sell
-7,500
Closed -$1.93M – 1288
2024
Q4 		$1.76M Sell
7,500
-10,762
-59% -$2.83M 0.01% 682
2024
Q3 		$5.02M Sell
18,262
-11,738
-39% -$3.06M 0.02% 412
2024
Q2 		$7.29M Sell
30,000
-92,500
-76% -$14.6M 0.03% 301
2024
Q1 		$18.3M Buy
122,500
+40,000
+48% +$6.67M 0.1% 112
2023
Q4 		$15.8M Buy
82,500
+36,600
+80% +$6.23M 0.1% 128
2023
Q3 		$8.13M Buy
+45,900
New +$8.76M 0.06% 190
2021
Q1 		– Sell
-20,000
Closed -$2.6M – 852
2020
Q4 		$2.6M Buy
+20,000
New +$2.67M 0.03% 336
2020
Q1 		– Sell
-60,000
Closed -$6.91M – 493
2019
Q4 		$6.91M Sell
60,000
-300
-0.5% -$29.9K 0.15% 132
2019
Q3 		$4.85M Sell
60,300
-154,700
-72% -$12.2M 0.13% 154
2019
Q2 		$15.6M Buy
215,000
+165,000
+330% +$12.7M 0.36% 52
2019
Q1 		$4.67M Sell
50,000
-5,000
-9% -$418K 0.06% 292
2018
Q4 		$4.01M Sell
55,000
-5,000
-8% -$385K 0.05% 355
2018
Q3 		$5.25M Buy
60,000
+30,000
+100% +$3.02M 0.06% 270
2018
Q2 		$2.96M Buy
+30,000
New +$2.98M 0.04% 427

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's ALNY Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 272% in Q2 2026, buying an estimated $32.8M and bringing the position to 148,720 shares worth $44.8M. The position accounts for 0.12% of the portfolio, ranked #128.

Hudson Bay Capital Management first reported a position in ALNY in Q2 2018 and has held it in 19 quarters since. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Hudson Bay Capital Management held 148,720 shares of Alnylam Pharmaceuticals worth $44.8M as of Q2 2026.
  • Hudson Bay Capital Management bought 108,720 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $32.8M.
  • Alnylam Pharmaceuticals made up 0.12% of Hudson Bay Capital Management's portfolio in Q2 2026, its #128 holding.
  • Hudson Bay Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2018 and has held it in 19 quarters since.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.